Idaho,
Good overview and explanation of the real need and eventual acceptance of Hylenex for fluid and drug delivery. As with all things revolutionary, acceptance is slow in the beginning.
One market you did not mention and perhaps the largest potential market is Nursing Homes. Veinous access is often difficult or impossible even when not dehydrated. Dehydration is a common problem with the elderly and Hylenex would eliminate trips to ER. This market is being explored in test Nursing Homes by Baxter and no further clinical trials may be required. We are supposed to know about this market first half 2009.
Since no one addressed the false $800 million potential market being repeated over and over, I will in this post. Baxters first projected full penetration was $300 million. At their 2007 pipeline update analyst meeting they increased the target to $500 million for full market penetration annual revenue. If memory serves, Opthomology is projected at $25 million and pediatric is projected at $160 million. This leaves $315 million for all other uses with none of those potential market sizes revealed.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
Market Data 
Markets 
AI
